AHA Conference 2024 - Long-term safety and efficacy outcomes from 48 and 72 weeks of LIB003 (LIB Therapeutics LLC) administered to patients with CVD or at high risk for CVD on oral lipid-lowering therapy (LLT) who completed one of the phase 3 base studies.

Dr Dean Kereiakes (The Ohio State University, Ohio, US) joins us onsite at AHA Conference to discuss the findings from LIBerate-OLE (NCT04798430).

LIBerate-OLE is an open-label, phase 3, extension trial investigating the use of LIB003 in patients with CVD or at high risk for CVD on LLT. Approximately 2,000 patients were enrolled in the study and were seen in the clinic for the initial 12 weeks and then every 12 weeks, with the interim doses administered at home. The primary outcome measure was the incidence of treatment-emergent adverse events after 48 and 72 weeks.

Interview Questions:
1.    What is the reasoning behind the trial?
2.    Could you tell us about the mechanism of action behind lerodalcibep?
3.    What was the study design and patient population for  LIBerate-OLE?
4.    What were the key findings?
5.    What are the take-home messages for practice?
6.    What further research is needed in this area?

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.